Houston institutions have landed $6.25 million in NIH funding to launch the HAI-KUH research training program. Photo via UH.

Institutions within Houston’s Texas Medical Center have launched the Houston Area Incubator for Kidney, Urologic and Hematologic Research Training (HAI-KUH) program. The incubator will be backed by $6.25 million over five years from the National Institutes of Health and aims to create a training pipeline for researchers.

HAI-KUH will include 58 investigators from Baylor College of Medicine, Texas Children’s Hospital, the University of Texas Health Science Center at Houston, University of Houston, Houston Methodist Research Institute, MD Anderson Cancer Center, Rice University and Texas A&M University Institute of Biosciences and Technology. The program will fund six predoctoral students and six postdoctoral associates. Trainees will receive support in scientific research, professional development and networking.

According to the organizations, Houston has a high burden of kidney diseases, hypertension, sickle cell disease and other nonmalignant hematologic conditions. HAI-KUH will work to improve the health of patients by building a strong scientific workforce that leverages the team's biomedical research resources to develop research skills of students and trainees and prepare them for sustained and impactful careers. The funding comes through the National Institute of Diabetes and Digestive and Kidney Diseases.

The principal investigators of the project include Dr. Alison Bertuch, professor of pediatric oncology and molecular and human genetics at BCM; Peter Doris, professor and director of the Institute of Molecular Medicine Center for Human Genetics at UT Health; and Margaret Goodell, professor and chair of the Department of Molecular and Cellular Biology at Baylor.

“This new award provides unique collaborative training experiences that extend beyond the outstanding kidney, urology, and hematology research going on in the Texas Medical Center,” Doris said in a news release. “In conceiving this award, the National Institute of Diabetes and Digestive and Kidney Diseases envisioned trainee development across the full spectrum of skills required for professional success.”

Jeffrey Rimer, a professor of Chemical Engineering, is a core investigator on the project and program director at UH. Rimer is known for his breakthroughs in using innovative methods in control crystals to help treat malaria and kidney stones. Other co-investigators include Dr. Wolfgang Winkelmeyer (Baylor), Oleh Pochynyuk (UTHealth), Dr. Rose Khavari (Houston Methodist) and Pamela Wenzel (UT Health).

“This new NIH-sponsored training program will enable us to recruit talented students and postdocs to work on these challenging areas of research,” Rimer added in a release.

Baylor Genetics has paired with Baylor’s department of molecular and human genetics to launch the Medical Genetics Multiomics Laboratory with a goal for the collaboration is to turn research into clinical diagnostics. Photo via Getty Images

This new Houston lab is translating genetics research into clinical diagnostics

DNA innovation

A new lab at Baylor College of Medicine is primed to do groundbreaking work in the field of genetics.

Baylor Genetics has paired with Baylor’s department of molecular and human genetics to launch the Medical Genetics Multiomics Laboratory (MGML). The goal for the collaboration is to turn research into clinical diagnostics.

MGML’s freshly launched first clinical test is Whole Transcriptomic RNA Sequencing (WT RNAseq). The new test builds upon the success of existing tests like whole exome sequencing (WES) and whole genome sequencing (WGS) currently on offer from Baylor Genetics by focusing on additional variants that could be missed by the other tests.

Baylor Genetics is offering WT RNAseq to the Undiagnosed Diseases Network (UDN) and its affiliated institutions. For more than a decade, the NIH-funded UDN has united clinical and research experts from across many fields and institutions to give answers to patients with rare genetic diseases. Since it became one of the first institutions to join the UDN in 2014, Baylor Genetics has been the UDN’s sequencing core, using WES, WGS and RNA sequencing to help diagnose patients. The additional offering of WT RNAseq could improve the diagnostic yield by as much as 17 percent.

“This agreement, and the MGML lab, bring to life our vision of innovation, allowing us to co-develop new tests, evaluate in terms of clinical utility, and offer commercially in either a research or clinical setting,” says Dr. Brendan Lee, professor, chair and Robert and Janice McNair Endowed Chair of Molecular and Human Genetics at Baylor College of Medicine, and scientific advisory and board of directors member at Baylor Genetics. “Baylor Genetics is turning around critical high-volume testing, but the challenge is also maintaining our innovative edge and our position as leaders in discovery and genomic health implementation. This agreement is a realization of the vision when Baylor Genetics was founded 10 years ago.”

The lab’s product offerings will continue to expand as it becomes commercially feasible to do so, and the new tests will be used both commercially and clinically.

Baylor Genetics combines the powers of Baylor College of Medicine, which has the NIH’s best-funded department of molecular and human genetics, and Japanese clinical diagnostic testing company H.U. Group Holdings.

CellChorus created a visualization AI program that helps scientists to better understand the functioning of cells, including their activation, killing and movement. Photo via Getty Images

Houston health tech startup scores $2.5M SBIR grant to advance unique cell therapy AI technology

fresh funding

A Houston biotech company just announced a new award of $2.5 million.

CellChorus, a spinoff of the Single Cell Lab at the University of Houston, announced the fresh funding, which comes from an SBIR (Small Business Innovation Research) grant from the National Institute of Health (NIH) through its National Center for Advancing Translational Sciences (NCATS).

CellChorus is the business behind a technology called TIMING, which stands for Time-lapse Imaging Microscopy In Nanowell Grids. It’s a visualization AI program that helps scientists to better understand the functioning of cells, including their activation, killing and movement. This more in-depth knowledge of immune cells could be instrumental in developing novel therapies in countless disorders, including cancers and infectious diseases.

“While many cell therapies have been approved and are in development, the industry needs an integrated analytical platform that provides a matrix of functional readouts, including cell phenotype and metabolism on the same cells over time,” Rebecca Berdeaux, vice president of science at CellChorus, says in a press release. “We are grateful to NCATS for its support of the development of application-specific kits that apply dynamic, functional single-cell analysis of immune cell phenotype and function. The product we will develop will increase the impact of these therapies to improve the lives of patients.”

A two-year, $2.1 million Phase II grant will begin after the company achieves predetermined milestones under a $350,000 Phase I grant that is currently taking place. As Berdeaux explained, the funds will be used to develop TIMING kits which will manufacture analytics that provide end-users with rapid, specific and predictive results to accelerate translational research and the development and manufacture of more effective cell therapies.

TIMING is more than a great idea whose time has yet to come. It has already been proven in great depth. In fact, last June, CellChorus CEO Daniel Meyer told InnovationMap that he was initially attracted to the technology because it was “very well validated.” At the time, CellChorus had just announced a $2.3 million SBIR Fast-Track grant from the National Institute of General Medical Sciences. The company also went on to win an award in the Life Science category of the 2023 Houston Innovation Awards.

That confirmation of success comes from more than 200 peer-reviewed papers that describe myriad cell types and types of therapy, all of which used data from TIMING assays. TIMING data has benefited industry leaders in everything from research and clinical development to manufacturing. With the new grant, TIMING will become more widely available to scientists making important discoveries relating to the inner workings of the cells that drive our immunity.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Texas ranks among 10 best states to find a job, says new report

jobs report

If you’re hunting for a job in Texas amid a tough employment market, you stand a better chance of landing it here than you might in other states.

A new ranking by personal finance website WalletHub of the best states for jobs puts Texas at No. 7. The Lone Star State lands at No. 2 in the economic environment category and No. 18 in the job market category.

Massachusetts tops the list, and West Virginia appears at the bottom.

To determine the most attractive states for employment, WalletHub compared the 50 states across 34 key indicators of economic health and job market strength. Ranking factors included employment growth, median annual income, and average commute time.

“Living in one of the best states for jobs can provide stable conditions for the long term, helping you ride out the fluctuations that the economy will experience in the future,” WalletHub analyst Chip Lupo says.

In September, Gov. Greg Abbott announced Texas led the U.S. in job creation with the addition of 195,600 jobs over the past 12 months.

“Texas is America’s jobs leader,” Abbott says. “With the best business climate in the nation and a skilled and growing labor force, Texas is where businesses invest, jobs grow, and families thrive. Texas will continue to cut red tape and invest in businesses large and small to spur the economic growth of communities across our great state.”

While Abbott proclaims Texas is “America’s jobs leader,” the state’s level of job creation has recently slowed. In June, the Federal Reserve Bank of Dallas noted that the state’s year-to-date job growth rate had dipped to 1.8 percent, and that even slower job growth was expected in the second half of this year.

The August unemployment rate in Texas stood at 4.1 percent, according to the Texas Workforce Commission. Throughout 2025, the monthly rate in Texas has been either four percent or 4.1 percent.

By comparison, the U.S. unemployment rate in August was 4.3 percent, according to the U.S. Bureau of Labor Statistics. In 2025, the monthly rate for the U.S. has ranged from 4 percent to 4.3 percent.

Here’s a rundown of the August unemployment rates in Texas’ four biggest metro areas:

  • Austin — 3.9 percent
  • Dallas-Fort Worth — 4.4 percent
  • Houston — 5 percent
  • San Antonio — 4.4 percent

Unemployment rates have remained steady this year despite layoffs and hiring freezes driven by economic uncertainty. However, the number of U.S. workers who’ve been without a job for at least 27 weeks has risen by 385,000 this year, the Bureau of Labor Statistics reported in August. That month, long-term unemployed workers accounted for about one-fourth of all unemployed workers.

An August survey by the Federal Reserve Bank of New York showed a record-low 44.9 percent of Americans were confident about finding a job if they lost their current one.

TMC, Memorial Hermann launch partnership to spur new patient care technologies

medtech partnership

Texas Medical Center and Memorial Hermann Health System have launched a new collaboration for developing patient care technology.

Through the partnership, Memorial Hermann employees and physicians will now be able to participate in the TMC Center for Device Innovation (CDI), which will assist them in translating product innovation ideas into working prototypes. The first group of entrepreneurs will pitch their innovations in early 2026, according to a release from TMC.

“Memorial Hermann is excited to launch this new partnership with the TMC CDI,” Ini Ekiko Thomas, vice president of information technology at Memorial Hermann, said in the news release. “As we continue to grow (a) culture of innovation, we look forward to supporting our employees, affiliated physicians and providers in new ways.”

Mentors from Memorial Hermann, TMC Innovation and industry experts with specialties in medicine, regulatory strategy, reimbursement planning and investor readiness will assist with the program. The innovators will also gain access to support systems like product innovation and translation strategy, get dedicated engineering and machinist resources and personal workbench space at the CDI.

“The prototyping facilities and opportunities at TMC are world-class and globally recognized, attracting innovators from around the world to advance their technologies,” Tom Luby, chief innovation officer at TMC Innovation Factor, said in the release.

Memorial Hermann says the partnership will support its innovation hub’s “pilot and scale approach” and hopes that it will extend the hub’s impact in “supporting researchers, clinicians and staff in developing patentable, commercially viable products.”

“We are excited to expand our partnership with Memorial Hermann and open the doors of our Center for Device Innovation to their employees and physicians—already among the best in medical care,” Luby added in the release. “We look forward to seeing what they accomplish next, utilizing our labs and gaining insights from top leaders across our campus.”